Skip to main content

Advertisement

SpringerLink
Log in

Hepatobiliary Complications of Inflammatory Bowel Disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Several hepatobiliary abnormalities have been described in association with inflammatory bowel disease (IBD), including primary sclerosing cholangitis (PSC), small duct PSC, chronic hepatitis, cryptogenic cirrhosis, cholangiocarcinoma, and cholelithiasis. PSC is the most common biliary condition in patients with IBD, with an incidence ranging from 2.5% to 7.5%. PSC usually progresses insidiously and eventually leads to cirrhosis independent of inflammatory bowel disease activity. There is a very high incidence of cholangiocarcinoma and an elevated risk for developing colon cancer in patients with PSC. Medical therapy has not proven successful in slowing disease progression or prolonging survival. Treatment of symptoms due to cholestasis, such as pruritis and steatorrhea, is an important aspect of the medical care of patients with PSC. Our preferred treatment of pruritis due to cholestasis is with bile acid binding exchange resins, such as cholestyramine or colestipol. Endoscopic manipulation is recommended for treating complications of recurrent cholangitis or worsening jaundice in the setting of a dominant stricture, but endoscopic approaches have not been conclusively demonstrated to improve survival or decrease the need for liver transplantation. Liver transplantation remains the only effective treatment of advanced PSC, and should be considered in patients with complications of cirrhosis or intractable pruritis or fatigue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:491–513.

    Article  PubMed  CAS  Google Scholar 

  2. Bambha K et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–9.

    Article  PubMed  Google Scholar 

  3. Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–7.

    Article  PubMed  Google Scholar 

  4. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:1929–30.

    Article  PubMed  Google Scholar 

  5. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.

    Article  PubMed  Google Scholar 

  6. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319–23.

    PubMed  CAS  Google Scholar 

  7. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195–9.

    Article  PubMed  CAS  Google Scholar 

  8. •• Chapman R, Fevery J, Kalloo A, et al. AASLD Practice guidelines: diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660–78. This is the current AASLD recommendations of the preferred approaches to the diagnosis and therapy of PSC. The guideline discusses variant forms of PSC, pharmacologic and surgical treatment of PSC, and complications related to dominant strictures and cholangiocarcinoma.

    PubMed  CAS  Google Scholar 

  9. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107–14.

    Article  PubMed  Google Scholar 

  10. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710–7.

    PubMed  CAS  Google Scholar 

  11. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688–94.

    Article  PubMed  CAS  Google Scholar 

  12. Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 1992;103:1893–901.

    PubMed  CAS  Google Scholar 

  13. Rudolph G, Gotthardt D, Kloters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149–55.

    Article  PubMed  Google Scholar 

  14. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology. 1997;25:1049–53.

    Article  PubMed  CAS  Google Scholar 

  15. Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut. 1992;33:657–62.

    Article  PubMed  CAS  Google Scholar 

  16. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006;4:514–20.

    Article  PubMed  Google Scholar 

  17. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc. 2006;64:219–23.

    Article  PubMed  Google Scholar 

  18. • Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010;256:387–96. MRC is the preferred imaging technology for confirming the diagnosis of PSC and has supplanted ERCP due to the invasive nature and potential for complications with ERCP.

    Article  PubMed  Google Scholar 

  19. Banerjee S, Shen B, Shen TH, et al. ASGE Standards of Practice Committee. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67:791–8.

    Article  PubMed  Google Scholar 

  20. Olsson R, Hagerstrand I, Broome U, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol. 1995;48:933–5.

    Article  PubMed  CAS  Google Scholar 

  21. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol. 2003;98:1155–8.

    Article  PubMed  Google Scholar 

  22. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95:1130–8.

    Article  PubMed  CAS  Google Scholar 

  23. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis. 1991;11:11–7.

    Article  PubMed  CAS  Google Scholar 

  24. Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975–80.

    Article  PubMed  Google Scholar 

  25. Angulo P, Maor-Kendler Y, Lindor K, et al. Small-duct primary sclerosing cholangitis: a long term follow-up study. Hepatology. 2002;35:1494–500.

    Article  PubMed  Google Scholar 

  26. Charatcharoenwitthaya P, Angulo P, Enders FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008;47:133–42.

    Article  PubMed  CAS  Google Scholar 

  27. •• Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706–15. A study of 53 patients with IgG4-associated cholangitis (IAC) describing the clinical presentation, serologic markers, imaging characteristics and treatment response.

    Article  PubMed  Google Scholar 

  28. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070–5.

    Article  PubMed  CAS  Google Scholar 

  29. Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28:209–20.

    Article  PubMed  CAS  Google Scholar 

  30. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–22.

    Article  PubMed  Google Scholar 

  31. Shi J, Li Z, Zeng X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: metaanalysis of randomized controlled trials. Hepatol Res. 2009;39:865–73.

    Article  PubMed  CAS  Google Scholar 

  32. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525–31.

    Article  PubMed  CAS  Google Scholar 

  33. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464–72.

    Article  PubMed  CAS  Google Scholar 

  34. •• Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808–14. A randomized, placebo-controlled trial indicating potential harmful effects on clinical course of PSC with high dose UDCA therapy.

    Article  PubMed  CAS  Google Scholar 

  35. • Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol advance online publication 2011;doi:10.1038/ajg.2011.156. Long-term use of high-dose UDCA was associated with a 4.4 fold increased risk of colorectal neoplasia in patients with UC and PSC.

  36. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.

    Article  PubMed  Google Scholar 

  37. Mela M, Mancuso A, Burroughs AK. Review article: pruritis in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857–70.

    Article  PubMed  CAS  Google Scholar 

  38. • Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180–8. Osteoporosis (T-score less than −2.5) was found in 15% of patients and occurred 23.8-fold (95% confidence interval, 4.6-122.8) more frequently in those with PSC than expected from a matched population. By multivariate analysis, age 54 years or older (odds ratio [OR], 7.8; 95% CI, 3.3–18.3), body mass index ≤24 kg/m(2) (OR, 4.9; 95% CI, 1.9–12.6), and inflammatory bowel disease for ≥19 years (OR, 3.6; 95% CI, 1.5–8.4) correlated with the presence of osteoporosis.

    Article  PubMed  Google Scholar 

  39. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271–8.

    Article  PubMed  CAS  Google Scholar 

  40. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003;125:937–40.

    Google Scholar 

  41. Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003;38:856–65.

    Article  PubMed  Google Scholar 

  42. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis:a randomized placebo-controlled trial. Hepatology. 2005;42:762–71.

    Article  PubMed  CAS  Google Scholar 

  43. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:502–8.

    Article  PubMed  Google Scholar 

  44. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–6.

    Article  PubMed  Google Scholar 

  45. MacCarty RL, LaRusso NF, May GR, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology. 1985;156:43–6.

    PubMed  CAS  Google Scholar 

  46. Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc. 1991;37:38–43.

    Article  PubMed  CAS  Google Scholar 

  47. Lee JG, Schutz SM, England RE, et al. Endoscopic therapy of sclerosing cholangitis. Hepatology. 1995;21:661–7.

    PubMed  CAS  Google Scholar 

  48. Van Milligen de Wit AW, van Bracht J, Rauws EA, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1996;44:293–9.

    Article  PubMed  CAS  Google Scholar 

  49. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308–12.

    PubMed  CAS  Google Scholar 

  50. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1059–66.

    Article  PubMed  CAS  Google Scholar 

  51. Ponsioen C, Lam K, van Milligen de Wit A, et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:2403–7.

    Article  PubMed  CAS  Google Scholar 

  52. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 1997;26:560–6.

    Article  PubMed  CAS  Google Scholar 

  53. Gluck M, Cantone NR, Brandabur JJ, et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032–9.

    Article  PubMed  Google Scholar 

  54. Van Milligen de Wit AW, Rauws EA, van Bracht J, et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1997;46:344–7.

    Article  PubMed  CAS  Google Scholar 

  55. Ahrendt SA, Pitt HA, Kallo AK, et al. Primary sclerosing cholangitis. Resect, dilate, or transplant? Ann Surg. 1998;227:412–23.

    Article  PubMed  CAS  Google Scholar 

  56. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol. 2003;38:1176–83.

    Article  PubMed  CAS  Google Scholar 

  57. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 1997;225:472–83.

    Article  PubMed  CAS  Google Scholar 

  58. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma:is transplantation an option? For whom? J Hepatol. 2007;47:455–9.

    Article  PubMed  Google Scholar 

  59. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002;8:575–81.

    Article  PubMed  Google Scholar 

  60. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138–43.

    Article  PubMed  Google Scholar 

  61. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14:181–5.

    Article  PubMed  Google Scholar 

  62. Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after liver transplantation: a review. Dig Surg. 2008;25:245–57.

    Article  PubMed  Google Scholar 

  63. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321–7.

    Article  PubMed  Google Scholar 

  64. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790–4.

    PubMed  CAS  Google Scholar 

  65. Loftus Jr EV et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.

    Article  PubMed  Google Scholar 

  66. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46–55.

    Article  PubMed  Google Scholar 

  67. • Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64. A total of 211 patients with PSC were included, 143 (68%) were male and 126 (60%) had IBD. The risk of cholangiocarcinoma after 10 years was 9%. In patients with concomitant IBD the 10-year and 20-year risks for CRC were 14% and 31%, respectively.

    Article  PubMed  Google Scholar 

  68. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis:a meta-analysis. Gastrointest Endosc. 2002;56:48–54.

    Article  PubMed  Google Scholar 

  69. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:52–6.

    Article  PubMed  Google Scholar 

  70. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.

    Article  PubMed  Google Scholar 

  71. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–21.

    Article  PubMed  Google Scholar 

  72. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.

    Article  PubMed  Google Scholar 

  73. Pardi DS, Loftus Jr EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–93.

    Article  PubMed  CAS  Google Scholar 

  74. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95.

    PubMed  CAS  Google Scholar 

  75. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35:380–4.

    Article  PubMed  Google Scholar 

  76. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75:1983–8.

    Article  PubMed  Google Scholar 

  77. Brandt DJ, MacCarty RL, Charboneau JW, LaRusso NF, Wiesner RH, Ludwig J. Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol. 1988;150:571–4.

    CAS  Google Scholar 

  78. Buckles DC, Lindor KD, Larusso NF, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97:1138–42.

    Article  PubMed  Google Scholar 

  79. Lewis JT, Talwalkar JA, Rosen CB, et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis:evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007;31:907–13.

    Article  PubMed  Google Scholar 

  80. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48:598–605.

    PubMed  Google Scholar 

  81. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6.

    Article  PubMed  Google Scholar 

  82. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123–35.

    Article  PubMed  CAS  Google Scholar 

  83. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case—control study. Hepatology. 2000;31:7–11.

    Article  PubMed  CAS  Google Scholar 

  84. Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology. 2008;47:90–6.

    Article  PubMed  CAS  Google Scholar 

  85. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205–11.

    Article  PubMed  CAS  Google Scholar 

  86. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108:865–9.

    Article  PubMed  CAS  Google Scholar 

  87. Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum Ca19–9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993;68:874–9.

    PubMed  CAS  Google Scholar 

  88. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734–40.

    Article  PubMed  CAS  Google Scholar 

  89. • Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106–17. A study looking at the value of CA 19–9 combined with cross-sectional liver imaging and cholangiography with cytologic examination to diagnose cholangiocarcinoma in patients with PSC.

    Article  PubMed  CAS  Google Scholar 

  90. Ferrari Junior AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc. 1994;40:140–5.

    Article  PubMed  CAS  Google Scholar 

  91. Rumalla A, Baron TH, Leontovich O, et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Mayo Clin Proc. 2001;76:29–33.

    Article  PubMed  CAS  Google Scholar 

  92. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy. 1999;31:305–9.

    Article  PubMed  CAS  Google Scholar 

  93. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56:40–7.

    Article  PubMed  Google Scholar 

  94. Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy. 2006;38:665–9.

    Article  PubMed  CAS  Google Scholar 

  95. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131:1064–72.

    Article  PubMed  Google Scholar 

  96. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–8. discussion 458–461.

    PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Section of Gastroenterology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA

    David R. Lichtenstein

Authors
  1. David R. Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David R. Lichtenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lichtenstein, D.R. Hepatobiliary Complications of Inflammatory Bowel Disease. Curr Gastroenterol Rep 13, 495–505 (2011). https://doi.org/10.1007/s11894-011-0213-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-011-0213-9

Keywords

Search

Navigation